Over the span of a decade, the way Australian medicine addresses iron deficiency in women of reproductive age has been quietly transformed. What was once a rare clinical intervention — intravenous iron infusion — is now received by one in twenty women annually, a seventeen-fold rise that reflects both growing awareness of iron deficiency's debilitating reach and a healthcare system still working to ensure that expanded access translates into equitable, completed care. The surge in treatment, and the $82 million in public spending it now commands, invites a deeper question: whether a medicine's
Iron IV use among Australian women surges 17-fold in a decade
Iron deficiency causes debilitating fatigue, poor concentration, and reduced quality of life in affected women; treatment completion barriers may leave some women undertreated.